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ABSTRACT
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor 
mediating the toxicity and tumor-promoting properties of dioxin. AHR has been 
reported to be overexpressed and constitutively active in a variety of solid tumors, but 
few data are currently available concerning its role in thyroid cancer. In this study we 
quantitatively explored a series of 51 paired-normal and papillary thyroid carcinoma 
(PTC) tissues for AHR-related genes. We identified an increased AHR expression/
activity in PTC, independently from its nuclear dimerization partner and repressor but 
strictly related to a constitutive active MAPK/ERK pathway. The AHR up-regulation 
followed by an increased expression of AHR target genes was confirmed by a meta-
analysis of published microarray data, suggesting a ligand-independent active AHR 
pathway in PTC. In-vitro studies using a PTC-derived cell line (BCPAP) and HEK293 
cells showed that BRAFV600E may directly modulate AHR localization, induce AHR 
expression and activity in an exogenous ligand-independent manner. The AHR pathway 
might represent a potential novel therapeutic target for PTC in the clinical practice.
INTRODUCTION
Thyroid cancer is considered the most common 
endocrine malignancy and the incidence of papillary 
thyroid carcinoma (PTC), its most frequent histologic 
subtype - representing approximately 80% of all thyroid 
cancers - [1], is rapidly increasing [2].
About 36%-69% of PTCs harbor activating 
mutations in the BRAF gene (v-raf murine sarcoma 
viral oncogene homolog B1), which encodes a member 
of the raf/mil family of serine/threonine kinases. BRAF 
functions to regulate the MAPK/ERK pathway transducing 
extracellular stimuli to the nucleus [3]. Active BRAF 
phosphorylates and activates MEK1/2 beginning a kinase 
cascade that, through ERK1/2, signals for ligand- and cell-
specific responses. More than 90% of the BRAF mutated 
PTCs are characterized by a T1799A transversion that 
results in the V600E aminoacidic substitution (BRAFV600E) 
within the activating domain of the protein [4]. Disrupting 
hydrophobic interactions, BRAFV600E enables the protein 
to fold into a catalytically active form with a nearly 
500-fold increased kinase activity [5]. This event leads 
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to the activation of the downstream signaling cascade 
in the absence of extracellular stimuli, allowing the cell 
to become self-sufficient in growth signals within this 
pathway [6]. In transgenic mice, BRAFV600E induces the 
development of thyroid cancer with high penetrance 
and short latency, thus suggesting that BRAF mutations 
may function as the initial transforming event during 
thyroid tumor development [7]. All these data support the 
central role of BRAFV600E and MAPK signaling pathway 
in transformation in PTC, however the mechanism of 
concomitant activation of different signaling pathways by 
BRAFV600E and their effects in thyroid cancer are not fully 
elucidated.
Aryl hydrocarbon receptor (AHR) is a ligand-
activated transcription factor that mediates the 
effects of many environmental pollutants, including 
polycyclic aromatic hydrocarbons (PAH) and 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), through 
the induction of several phase I (e.g. CYP1A1, CYP1B1) 
and II biotransforming enzymes (e.g. UDP-glucoronosyl 
transferase UGT1A6, NADPH-quinone-oxidoreductase, 
NQO1) [8]. In its ligand-free inactive form, the AHR is a 
cytosolic protein complexed to two HSP90 molecules, the 
HSP90-interacting protein p23 and the AHR-interacting 
protein AIP [9]. Upon ligand binding, AHR translocates 
to the nucleus where it heterodimerizes with the aryl 
hydrocarbon nuclear translocator (ARNT). This active 
complex binds to xenobiotic-response elements (XRE) 
located in the enhancer/promoter regions, thus regulating 
the expression of target genes [8].
AHR has long been studied for its role in mediating 
TCDD toxicity [10]. However, its involvement in many 
other biological processes, including development, 
immunity and cancer biology, is strongly emerging 
[8, 11, 12]. AHR is overexpressed and constitutively 
active in a variety of tumor types, in cancer cell lines and 
in tumors from animal models, where it mostly shows 
a pro-oncogenic role [12]. A recent study on multiple cell 
lines from the Cancer Cell Line Encyclopedia reported 
relative high level of AHR mRNA in some cellular models 
of solid tumor (e.g. pancreatic, liver and chondrosarcoma 
derived cell lines); low levels were instead detected in 
many leukemia subtypes [13]. More recently, investigating 
the role of genetic events responsible for the onset of the 
thyroid cancer in acromegaly, we have shown that AHR 
is selectively overexpressed in a small cohort of PTC 
compared to the normal surrounding tissue. We found, 
in addition, that such increase was more marked in PTC 
samples harboring BRAFV600E, irrespective of acromegaly 
status [14]. Given the proven cross-talk between AHR and 
MAPK pathway [15] and the role of AHR in modulating 
growth and migration of cancer cells [12], in the present 
work we aim to confirm previous associations between 
the BRAFV600E and AHR overexpression in a large, 
independent cohort of patients with PTC. In addition, 
cellular models of PTC are used to systematically analyze 
the expression levels of other components of the AHR 
signaling pathway, and to better elucidate the molecular 
link between BRAFV600E and AHR in thyroid tumor.
RESULTS
AHR, AHRR and ARNT expression in tumor 
and paired normal tissue
To ascertain the possible role of the components of 
the AHR pathway in the pathogenesis of PTC, the steady-
state levels of AHR, AHRR and ARNT mRNAs in tumoral 
specimens and paired normal tissues were evaluated by 
quantitative Real-time PCR (qPCR). The mean expression 
levels of AHRR (2.27 ± 1.80 vs 1.81 ± 2.06, p = 0.065) and 
ARNT (1.68 ± 0.70 vs 1.62 ± 0.89, p = 0.843) were similar 
in tumoral and paired normal tissue from 51 PTC, while 
a significant increase of AHR (3.36 ± 2.83 vs 2.08 ± 1.84, 
p < 0.0001, Figure 1A) was observed.
PTCs were then grouped according to the BRAF 
mutational status, being mutated in 49% (25/51) of cases, 
and possible differences in term of AHR expression were 
investigated. As shown in Figure 1 (Panels B and C), 
significant differences between tumoral and normal tissues 
could be observed in the BRAF mutated PTCs (mean 
of differences 1.88, 95% CI: 1.16–2.59, p < 0.0001), 
but not in those carrying the wild-type form (0.69, 
95% CI: 0.17–1.55, p = 0.20). Moreover, as expected, 
BRAFV600E cases expressed AHR at a higher level than 
the BRAFwt (2.27 ± 1.01 vs 1.44 ± 1.21, p = 0.0003, 
Figure 1D). Conversely, we could not find any correlation 
when samples were grouped according to RAS genes 
mutational status.
Parallel western blot experiments testing AHR 
expression in normal/tumoral match-pair samples showed 
a good positive correlation between AHR mRNA and 
protein expression. This confirms that the difference in 
AHR expression between PTC and its normal paired tissue 
was significantly higher in tumors carrying the BRAFV600E 
compared to BRAFwt PTC (Figure 1E).
AHR protein expression was then evaluated in 
tumoral specimens by immunohistochemistry. As shown 
in Figure 1F and in accordance with a previous report [14], 
a weak cytoplasmic and nuclear AHR immunostaining 
was observed in normal thyroid areas surrounding the 
neoplastic tissue. In BRAFV600E PTC cases a strong 
and homogeneous cytoplasmic AHR staining has been 
detected. Conversely, BRAFwt PTC samples displayed 
lower cytoplasmic or absent AHR staining (Figure 1G).
To further validate the AHR expression trend 
observed in our series, and to establish if this might be 
associated to an increased AHR signaling, a large-scale 
meta-analysis of microarray data in the public domain has 
been performed. Gene expression data from five previously 
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Figure 1: AHR expression in PTC. Box plots of relative qPCR gene expression measurements of AHR in either all PTCs A. only 
the BRAFV600E B. or BRAFwt C. PTCs and the relative paired normal tissues. Each value was referred to a pool of normal thyroid tissues 
that was set to 1. In D. the AHR expression of BRAFV600E vs BRAFwt PTCs is shown. For each sample the reported value represents the 
fold increase in tumoral specimen compared to its normal counterpart, which was set to 1. Boxes indicate the range from lower to upper 
quartile values, with the line inside the box representing the median. The vertical lines mark the highest and lowest value observed within 
a distance of 1.5 times the inter-quartile range from the bottom and the top of the boxes, respectively. Each dot represents a single sample. 
E. Representative Western blot analysis of normal/tumoral match-pair samples for the expression of AHR, phospho-ERK and total ERK. 
Samples were corrected for protein loading by β-Actin and the BRAF mutational status was reported on the top. AHR immunostaining in 
BRAFV600E F. and in BRAFwt G. PTC samples. Normal thyroid areas surrounding cancer cells are also visible. Original magnification x40.
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published microarray datasets were retrieved from GEO 
and integrated with a custom methodology. Patients’ tissue 
samples included normal thyroid (NT, n = 73), follicular 
thyroid carcinoma (FTC, n = 14), poorly differentiated 
thyroid carcinoma (PDTC, n = 4), PTC (n = 128) and 
anaplastic thyroid carcinoma (ATC, n = 22). Expression 
data showed an upregulation of AHR in PTC compared 
to normal thyroid tissues (p < 0.0001, Supplemental 
Figure 1A), while ARNT did not show significant 
differences between the two groups. We then evaluated 
the expression of phase I (e.g. CYP1A1 and CYP1B1) and 
phase II (e.g. NQO1) biotransforming enzymes. A four-
fold increase of CYP1B1 was observed in PTC compared 
to NT (Supplemental Figure 1B), while only a slight 
1.5-fold increase was observed for NQO1 (p < 0.0001) 
(Supplemental Figure 1C). In contrast, CYP1A1 did not 
significantly change between the two groups (Supplemental 
Figure 1D). Clinical meta data associated to expression 
profiles were further analyzed to assess if AHR transcription 
expression may be a function of thyroid disease progression 
or histotype. In spite of the different groups’ size and the 
lack of a statistical significance, in FTC, AHR expression 
was lower than NT, while ATC showed expression levels 
higher than NT but similar to PTC (Supplemental Figure 2).
To correlate clinical phenotype with AHR 
expression, the 51 PTC patients in our series were divided 
into 2 groups (AHR high- or low-expressing PTCs) 
according to the receptor median expression values. 
The clinico-pathological features of the 51 PTC patients 
were summarized in supplemental Table 1. At the end 
of a median follow-up of 65 months, 80% of patients 
were cured, 16% showed a persistent disease, while 4% 
deceased during the follow-up. Although PTC patients 
with high AHR expression levels showed preferentially 
low (I and II) than high (III and IV) PTC stages (68% 
vs 32%) – low AHR expressing cases are instead equally 
shared between the two groups – no significant correlation 
between AHR expression and patients’ age, tumor size, 
lymph node and distant metastases, and poor outcome 
could be established.
AHR expression in thyroid cell lines and effect of 
BRAFV600E on AHR expression
AHR expression levels were then assessed in four 
thyroid cell lines, all but one (TT) carrying the BRAFV600E 
in either a homozygous (BCPAP) or heterozygous state 
(K1 and 8505C). As shown in Figure 2, 8505C showed 
the highest expression both at mRNA and at protein level. 
AHR was instead detected at lower but similar protein 
levels in BCPAP and K1, while apparently no expression 
was found in TT cell line.
To exclude that the association between BRAFV600E 
and AHR overexpression was fortuitous and to 
ascertain if an active BRAF protein up-regulates AHR, 
the BRAFwt HEK293 cells, were co-transfected with 
a human BRAFV600E and a reporter plasmid in which 
luciferase expression is driven by AHR, through XRE 
elements. The constitutively active BRAFV600E induces 
a significant increase in luciferase activity compared to 
mock transfected cells (44% ± 13%, p < 0.01, Figure 3A). 
Interestingly, this positive stimulus could be reversed 
by the kinase inhibitor SB590885 acting on both the 
exogenous BRAFV600E and/or the endogenous BRAF, in 
a dose dependent manner (Figure 3A). To establish the 
reason for such increase, quantitative and qualitative 
evaluations of BRAFV600E effect on AHR expression and/
or localization were performed. BRAFV600E apparently 
does not induce AHR expression (Figure 3B), but rather 
a tendency to increase nuclear translocation (Figure 3C).
To further study the effect of BRAF inhibitors on 
AHR expression in thyroid-originating tumor cells, the 
BRAFV600E carrying cell lines were treated with RAF265 
or SB590885, which exert their inhibitory activity with 
more potency towards BRAF active conformation than the 
inactive one [4]. As expected p-ERK was strongly reduced 
in all cell lines after both treatments. In the BCPAP the 
inhibited BRAF activity is followed by a significant 
decrease of AHR expression (Figure 4A) and activity 
(Figure 4B), while no effect could instead be observed in 
8505C and K1 (Figure 4A).
DISCUSSION
AHR has been considered for years as a major 
regulator of xenobiotic-induced carcinogenesis. Now 
it is becoming widely recognized that AHR and its 
abnormal expression play an important role in multiple 
stages of tumor development and progression. Several 
recently published works, demonstrated that even in the 
absence of exogenous ligands, AHR is overexpressed and 
constitutively active in a variety of human and/or rodent 
tumors including breast cancer, lung adenocarcinoma, 
pancreatic and prostate cancer [12, 16, 17].
In the present work, we clearly demonstrated in 
a large series of PTC – and further confirmed by data 
emerging from a large-scale meta-analysis of microarray 
studies in thyroid tumors – an increased expression/activity 
of AHR, independently from its nuclear dimerization 
partner ARNT and its repressor AHRR, but strictly related 
to a constitutive active MAPK/ERK pathway.
A strong body of evidences supports the mutual 
interaction between the AHR and MAPK/ERK pathways 
[15, 18]. Our finding that BRAFV600E mutation modulates 
AHR levels, localization and activity in PTC in an 
exogenous ligand-independent manner further reinforces 
this concept. Previous reports demonstrated that typical 
AHR activators (e.g. TCDD, benzo[a]pyrene) trigger 
MAP kinases at different levels and in different cellular 
systems [15, 18]. On the other hand, MAPK are key 
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players in regulating AHR function and stability [19–21]. 
Changes in the AHR levels and the enhanced TCDD-
initiated transactivation potential of the receptor have been 
indeed observed in cell overexpressing constitutively active 
ERK1 or MEK1 [20, 22]. Moreover, AHR is significantly 
expressed in a large subset of N-RAS mutated cell lines 
whose sensitivity to the MEK inhibitor PD0325901 
positively correlates with the receptor expression [13]. The 
direct or indirect involvement of serine/threonine kinases 
in AHR function regulation is further strengthened by the 
observation that phosphorylation of AHR co-chaperons 
HSP90 and of AHR-associated ancillary proteins, including 
ARNT, modulates the formation of a functional cytosolic 
AHR multicomponent complex [23] and/or potentiates the 
transcriptional activity of AHR/ARNT complexes [20].
In most tumoral specimens in our series, AHR was 
abundantly expressed in the cytoplasm of papillary thyroid 
cancer cells and was instead absent in the normal adjacent 
tissue. Although our data do not permit to distinguish 
whether the BRAFV600E either induces an increased 
expression/stability or reduces AHR degradation, by 
analogy with ERK phosphorylation, we suggest that 
BRAFV600E might stabilize the AHR, increase its nuclear 
uptake and protect it from proteasome digestion [24]. As 
expected, cytosolic AHR overexpression may be associated 
to the consequent enhancement of AHR-regulated 
downstream gene expression induction [25]. Accordingly, 
by a large-scale meta-analysis of published microarray 
data we observed an increased phase I (CYP1B1) and 
phase II (NQO1) biotransforming enzymes, supporting the 
Figure 2: AHR expression in thyroid tumors derived cell lines. The PTC-derived BCPAP and K1, the medullary thyroid cancer 
cell line TT, and the 8505C established from an undifferentiated thyroid carcinoma were evaluated for AHR expression at both mRNA 
A. and protein level B. Samples were corrected for protein loading by β-Actin. Error bars represent standard deviations.
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Figure 3: Effect of BRAFV600E on AHR expression/activity in HEK293 cells. A. HEK293 cells were co-transfected with the 
XRE-luc reporter plasmid and either the human Flag-tagged BRAFV600E plasmid or the empty vector pcDNA3.1 and treated with increasing 
concentration of the BRAF inhibitor SB590885. The relative activity was adjusted for transfection efficiency using pRL-TK. Error bars 
represent standard deviation. ** reflects p < 0.01 value for luciferase activity in mock versus BRAFV600E transfected cells at basal level; 
# § reflect p < 0.01 values for treated versus untreated cells. B. Representative Western blot analysis of AHR in HEK293 cells transfected 
with either BRAFV600E or pcDNA3.1. β-Actin was used to normalize for loading variations. C. Immunofluorescence staining of Hoechst 
(blue), Flag (red) and AHR (green) in BRAFV600E transfected HEK293. Only one of three cells in the picture is positive for Flag-tagged 
BRAFV600E, for which an increased in nuclear AHR could be observed. All experiments were performed at least in triplicate.
Figure 4: Effect of BRAF inhibitors on AHR expression and activity in thyroid cell lines. A. Representative Western blot 
analysis of BCPAP, 8505C and K1 cells treated with IC50 doses of RAF265 and SB590885 for the expression of AHR, phospho-ERK and 
total ERK. Samples were corrected for protein loading by β-Actin. B. Relative luciferase activity of BCPAP cells transfected with XRE-luc 
and treated with RAF265 and SB590885 with the same concentration as above. Error bars represent standard deviation *p < 0.05, compared 
with a group given no drug treatment (one-way ANOVA). All experiments were performed at least in triplicate.
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idea that in PTC cells AHR can potentially heterodimerize 
with ARNT in the absence of ligands.
Three different aspects emerging from our cellular 
studies further support the inductive role of BRAFV600E on 
AHR expression/activity. 1- AHR is expressed in 8505C, 
BCPAP and at lower level in K1 all of them carrying the 
BRAFV600E, while it is barely detectable in the BRAFwt TT 
cells. Moreover, in HEK293 with a constitutively active 
MAPK pathway, the AHR activity was significantly 
increased. 2- The positive stimulus of BRAFV600E on 
AHR can be significantly reverted by kinases inhibitors 
in both BCPAP and HEK293. By specifically blocking 
BRAF, RAF265 and SB590885 therefore not only reduce 
cell proliferation and promote apoptosis in BCPAP as 
we previously demonstrated [4], but also inhibit AHR 
expression/activity pathway. Additional data could be 
provided by the use of selective MEK inhibitors. However, 
the possible concomitant effects of these drugs on AHR 
[26, 27], prevents their use for studying the effects of 
blocking the MAPK/ERK pathway downstream of BRAF 
on AHR activity. In K1 and 8505C cell lines, however, 
the inhibition of ERK phosphorylation is not accompanied 
by a decrease in AHR expression. The reason of this 
uncoupling is unclear, however it is reasonable to 
hypothesize that other molecular pathways may sustain 
AHR expression. Further studies would help clarifying 
this point. 3- The introduction of a constitutive active 
BRAFV600E in HEK293 induces AHR activity. This effect 
seems not to reflect an increase in AHR expression as 
observed in PTC tumoral specimens, but more likely an 
increased nuclear shuttling. This may reflects the tissue-
specific regulation of AHR localization [28].
Both AHR and CYP1B1 represent potential targets 
for chemoprevention in several cases. Some AHR agonists 
inhibit the growth of pancreatic cancer cells expressing 
AHR at high levels [29]. Many flavonoids may prevent 
or improve tumorigenic outcomes by reducing AHR 
and/or CYP1A1/CYP1B1 activity, or by preventing 
PAH-induced genotoxicity [30]. CYP1B1 represents a 
therapeutic target also for potential anticancer drugs that 
can be metabolically activated by this biotransforming 
enzyme [29]. For instance 3,4-Methylenedioxy-3′,4′,5′-
trimethoxy chalcone, has shown promise in the treatment 
and prevention of gastrointestinal tumors in mouse models 
[31]. Our data raise hence the possibility to consider 
AHR and CYP1B as possible novel therapeutic targets 
also for PTC. Anyway, the lack of any link between 
AHR expression and poor prognostic factors in our PTC 
series, together with the lack of any correlation with more 
de-differentiated histotypes from meta data analysis, 
prompt us to consider AHR as one of initial mediators of 
thyroid cancer development endorsed by BRAF, rather 
than a driver of the disease progression process.
In conclusion, this study supports end extends our 
previous findings concerning the relationship between 
BRAFV600E and AHR expression in human PTC [14]. 
Indeed, it provides the first evidence that BRAFV600E 
activating the MAPK/ERK signaling is able to upregulate 
the AHR pathway in these tumors, suggesting that 
targeting the AHR pathway might have potential 
therapeutic benefit in their clinical management. It raises, 
however also novel relevant issues we aim to clarify in 
the next future, including the role of the proteasome in 
the high AHR expression in mutated PTCs and the nature 
of the interaction between BRAF and AHR (i.e. direct 
or mediated through other proteins). Finally, as BRAF 
somatic mutations characterize other human malignancies 
including colon cancer and melanoma, future research 
should clarify if the BRAF-mediated AHR activation is 
peculiar of PTC or a more general mechanism.
MATERIALS AND METHODS
Patients, DNA extraction and mutation analysis
From 2010 to 2013, we collected a series of paired-
normal and PTC tissues from 51 patients: 17 males and 
34 females with a mean age 46 years (range 5–69) with 
a median follow-up of 65 months (range 15–79). All 
patients were treated with total thyroidectomy for PTC, 
and therapeutic neck dissection was performed in patients 
with standard indications. According to the 6th TNM 
classification 29 were stage I, 2 were stage II, 14 were 
stage III and 6 were stage IV. Follow-up or survival time 
was defined as the time from the initial surgical treatment 
to patient’s death due to PTC or to the most recent clinic 
visit. Patients gave written informed consent for their 
thyroid tissues to be used for research purposes. The local 
ethical committee approved the study.
DNA was extracted from frozen tissues after 
surgery using the DNeasy Blood and Tissue kit 
(Qiagen, Italy), according to the manufacturer’s 
protocol. Mutation analyses were performed for BRAF 
(NM_004333.4), N-RAS (NM_002524.3; exons 2 and 
3), K-RAS (NM_033360.2; exons 2 and 3), and H-RAS 
(NM_005343.2; exons 2 and 3) by direct sequencing, as 
described [14, 32].
Cell lines and treatments
Four human thyroid cell lines that have been recently 
authenticated to be unique thyroid cancer cell lines 
[33, 34], were used: the PTC-derived BCPAP (Leibniz 
Institute-DSMZ, Germany) and K1, the medullary thyroid 
cancer cell line TT, and the 8505C established from an 
undifferentiated thyroid carcinoma (ECACC, Sigma-
Aldrich, Italy). In addition, the human embryonic kidney 
HEK293 cell line (American Type Culture Collection, 
VA) was used for transfection experiments. All cell lines 
but HEK293, which was maintained in DMEM, were 
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cultured in RPMI 1640 (Gibco, Italy) supplemented with 
10% FBS (Gibco), L-glutamine (2 mM) and penicillin/
streptomycin (100 IU/mL/100 μg/mL, respectively). 
Adherent monolayer cultures were maintained in T75 
culture flasks and incubated at 37°C with 5% CO2 until 
they achieved 85% confluency. Cells were detached using 
0.25% trypsin (Sigma-Aldrich) and plated into T75 flasks 
at a density of 2 × 106 cells.
Novartis International (Basel, Switzerland) kindly 
provided RAF265, while SB590885 were purchased from 
Selleckchem (Houston, TX), and dissolved in DMSO 
following the manufacturer’s instructions. Cells were 
incubated with the drugs for 72 hours at the IC50 doses we 
recently established [4]. IC50 for RAF265 was 0.12 μM, 
0.55 μM and 1.32 μM in 8505C, BCPAP and K1 cells, 
respectively. IC50 for SB590885 was 5.2 μM in BCPAP 
and K1 cells and 6.2 μM in 8505C cells.
Cell transfection and dual-luciferase assay
Twenty-four hours before the experiment, BCPAP 
(2.5 × 105 cells/well) or HEK293 cells (2 × 105 cells/well) 
were seeded in 12-well plates. Cells were transiently 
transfected as reported elsewhere [35] using 2 μl of 
Lipofectamine 2000 (Invitrogen, Italy) and 1.5 μg of total 
DNA consisting of the Flag-tagged BRAFV600E/pcDNA3.1 
plasmids, and/or XRE-luc, and pRL-TK (Promega, Italy). 
After 6 hours incubation the medium was removed, 
proteins harvested in passive lysis buffer and the relative 
luciferase activity measured with the Dual Luciferase 
Reporter Assay System and a GloMax 20/20 luminometer 
(Promega), according to the manufacturer’s instructions.
Immunofluorescence microscopy
HEK293 cells were seeded in cover-glass-bottom 
microwell dishes and transfected with either the Flag- 
tagged BRAFV600E plasmid or the empty vector pcDNA3.1, 
as described above. After 24 h, cells were washed 
twice with PBS, fixed in 4% paraformaldehyde in PBS 
for 10 min at room temperature, and permeabilized 
incubating with 0.3% Triton X-100 and BSA 3% in PBS 
for 30 min. Cells were stained for endogenous AHR and 
exogenous BRAF, by incubating with a 1:300 rabbit anti-
FLAG polyclonal antibody (F7425, Sigma-Aldrich) and 
a mouse anti-AHR monoclonal antibody (clone 3B12, 
Novus Biologicals, 1:100) for 1 h at RT. The cells were 
then washed three times in PBS and incubated with 
AlexaFluor™ 488 or 594-labeled secondary antibodies 
(1:250 dilution) (Life Technologies, Italy) for 1 hour at RT. 
The cells were subsequently washed three times in PBS 
and nuclei counterstained with 1.5 μg/mL Hoechst 33258 
(Sigma-Aldrich) and mounted with Fluorescent Mounting 
Medium (Dako, Cat.No. S3023).
The preparations were examined with a Leica 
DMI6000CS fluorescence microscope (Leica 
Microsystems CMS) using a 100 × /1.40 oil-immersion 
objective. Images were acquired by means of a DFC365FX 
camera and analyzed with Leica LAS-AF 3.1.0 software.
Immunohistochemistry
In a subgroup of nineteen PTC cases (ten BRAFwt 
and nine carrying the BRAFV600E) for which enough 
material was available, immunohistochemistry was 
performed on formalin-fixed, paraffin-embedded 4–6 
μm thick tissue sections, using a polyclonal rabbit anti-
AHR antibody (sc-5579, Santa Cruz Biotechnology, USA, 
1:50). Appropriate positive and negative controls were 
run concurrently. Immunostaining for AHR was semi-
quantitatively scored as previously reported [14]. Two 
different pathologists assessed the analysis in blind. The 
intensity of the staining was indicated as weak, moderate 
or strong. The subcellular localization of staining was also 
considered (cytoplasmic, nuclear or both).
Meta-analysis of microarray expression data
Raw microarray gene expression profiles were 
obtained from the NCBI Gene Expression Omnibus 
(GEO) [36]. We considered five series (GSE53157 [37], 
GSE33630 [38], GSE29265, GSE3678 and GSE27155 
[39]), which comprise 294 samples. Based on tissue type, 
241 samples were selected, organized in a proper database, 
using the open source web application A-MADMAN 
[40] and considered for further analysis. For details, see 
Supplemental Materials and Methods.
Protein extraction and western blotting
Proteins were extracted from the different cell lines 
(6 × 105 cells into 60 mm cell culture dishes) possibly 
incubated with RAF265 and SB590885 as described 
elsewhere [41]. Briefly, cells were PBS-rinsed, lysed 
in RIPA buffer supplemented with proteases inhibitors 
and clarified by centrifugation. Available tumoral 
specimens and normal tissue pairs were re-suspended 
in lyses buffer and homogenized with Tissue Lyser 
(Qiagen). Protein concentrations were determined 
using the Bio-Rad DC protein assay kit (BioRad, 
Italy) following the manufacturer’s instructions. For 
each sample, 20 μg were resolved by SDS-PAGE on 
a 10% NuPAGE gel (Invitrogen) and transferred onto 
nitrocellulose membrane by Trans-Blot Turbo transfer 
system (BioRad). Membranes were blocked for 2 h 
with 5% non-fat dry milk, incubated overnight at 4°C 
with a primary antibody [1:1000 anti-AHR, (clone 
3B12, Novus Biological), 1:1000 anti-Erk1/2 and anti-
phospho-Erk1/2 (Thr202/Tyr204) (Cell Signaling, 
Euroclone, Italy)] followed by a 1 h incubation with 
an HRP-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories, US). Expression was 
Oncotarget32112www.impactjournals.com/oncotarget
corrected for differences in protein loading by probing 
blots with mouse anti-ß-actin antibody (1:5000, clone 
AC-15, Sigma-Aldrich). Blots were developed using 
Pierce ECL Substrate and exposed to CL-XPosure Film 
(Thermo Scientific, Rockford, US). Band intensity was 
quantified with Image J software 1.44p.
RNA isolation, reverse transcription and qPCR
Total RNA from frozen tissue after surgery, 
as well as from each thyroid cell line was extracted 
using TRIzol (Invitrogen) as previously reported [42]. 
RNA yield was determined on a spectrophotometer 
(NanoDrop Technologies, Wilmington, USA). One μg 
of DNase-treated RNA was reverse-transcribed using 
M-MuLV Reverse Transcriptase RNase H- (Euroclone) 
according to the manufacturer’s recommendations. qPCR 
experiments were performed according to the MIQE 
guidelines [43]. For details, see Supplemental Materials 
and Methods.
Statistical analysis
We calculated proportions and rates for categorical 
variables, means ± standard deviations, or medians 
and ranges for parametric or non-parametric variables. 
In qPCR experiments, groups were compared with 
the Mann-Whitney test or Wilcoxon test for quantitative 
variables not normally distributed. The MedCalc 
version 14.7 (MedCalc software, Ostand, Belgium) was 
used to manage patients’ dataset and for the statistical 
analyses. The significance level was set at p < 0.05 
for all tests.
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